A study identified several immune-related biomarkers that can potentially distinguish and predict neoadjuvant chemotherapy treatment in patients with breast cancer (BC).
Investigators analyzed a dataset from the Gene Expression Omnibus database comprising 159 BC patients. Differently expressed genes (DEGs) were procured by comparing patients with residual disease (RD) and patients with pathological complete response (pCR).
The study identified 9 immune-related biomarkers that intersected with DEGs and immune-related genes. According to the results, CXCL9, CXCL10, CXCL11, CXCL13, GZMB, IDO1, and LYZ were highly expressed in pCR patients compared with RD patients. CXCL14 and ESR1 were observed to be lowly expressed in pCR patients.
These 9 biomarkers have significant potential for predicting pCR in BC patients, the researchers concluded.
Reference: Fang D, Li Y, Li Y, et al. Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis. Gland Surg. 2022;11(6):1026-1036. doi:10.21037/gs-22-234
